Modesitt Spotlights the Latest ADC Breakthroughs in Gynecologic Oncology

Susan C. Modesitt, MD, FACOG, FACS, sheds light on the latest research with antibody-drug conjugates across gynecologic cancers.

Related Keywords

Emory University ,Georgia ,United States ,Atlanta ,Susanc Modesitt , ,National Comprehensive Cancer Network ,Winship Cancer Institute Of Emory University ,Onclive State ,Science Summit ,Winship Cancer Institute ,Gynecologic Oncology ,Emory University School ,D ,Iacog ,Pacs ,Antibody Drug Conjugates ,Adcs ,Onclive State Of The Science Summit ,Trop2 And Her2 Targeted Adcs ,Minimizing Toxicities ,Mirvetuximab Soravtansine ,Trastuzumab Deruxtecan ,Sacituzumab Govitecan ,Tisotumab Vedotin ,Elahere ,Trodelvy ,Enhertu ,Tivdak ,